Amwill Health Care Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039537,
    "name": "Amwill Health",
    "stock_name": "Amwill Health",
    "full_name": "Amwill Health Care Ltd",
    "name_url": "stocks-analysis/amwill-health",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "40.65",
    "chg": 0.57,
    "chgp": "1.42%",
    "dir": 1,
    "prev_price": "40.08",
    "mcapval": "81.31 Cr",
    "mcap": "Micro Cap",
    "scripcode": 544353,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0U2L01017",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 3600,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/amwill-health-10039537-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Amwill Health overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amwill-health-overvalued-or-undervalued-3682998",
        "imagepath": "",
        "date": "2025-11-09 08:12:12",
        "description": "As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios supporting this assessment include a PE ratio of 9.06, an EV to EBIT of 7.64, and an ROCE of 18.23%. \n\nIn comparison to its peers, Amwill Health's valuation metrics stand out, particularly against Sun Pharma, which is deemed expensive with a PE ratio of 35.17, and Divi's Lab, classified as very expensive with a PE ratio of 71.11. This stark contrast highlights Amwill Health's attractive valuation within the pharmaceuticals and biotechnology sector. Additionally, while Amwill Health has experienced a decline in stock price recently, it remains undervalued relative to its peers, reinforcing the potential for future upside...."
      },
      {
        "title": "Is Amwill Health overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amwill-health-overvalued-or-undervalued-3681968",
        "imagepath": "",
        "date": "2025-11-08 08:12:14",
        "description": "As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently deemed undervalued, with a PE ratio of 9.06, an EV to EBIT ratio of 7.64, and an EV to EBITDA ratio of 7.34. These figures suggest that Amwill Health is trading at a discount compared to its peers in the pharmaceuticals and biotechnology sector.\n\nIn comparison, Sun Pharma is classified as expensive with a PE ratio of 35.17, while Dr. Reddy's Labs is attractive with a PE of 17.43. This stark contrast highlights Amwill Health's favorable position in the market. Additionally, the company's return metrics, such as a ROCE of 18.23% and ROE of 14.68%, further reinforce its strong operational performance despite recent stock declines compared to the Sensex...."
      },
      {
        "title": "How has been the historical performance of Amwill Health?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-amwill-health-3672279",
        "imagepath": "",
        "date": "2025-11-04 23:00:10",
        "description": "Answer:\nThe historical performance of Amwill Health shows a fluctuating trend in key financial metrics over the past four years.\n\nBreakdown:\nAmwill Health's net sales increased from 27.61 Cr in Mar'22 to 43.95 Cr in Mar'24, before declining to 40.58 Cr in Mar'25. Total operating income followed a similar pattern, rising to 43.95 Cr in Mar'24 and then decreasing to 40.58 Cr in Mar'25. The total expenditure also rose from 23.95 Cr in Mar'22 to 28.93 Cr in Mar'25. Operating profit, excluding other income, peaked at 16.67 Cr in Mar'24 but fell to 11.65 Cr in Mar'25. Profit before tax showed a similar decline from 16.76 Cr in Mar'24 to 11.90 Cr in Mar'25, while profit after tax decreased from 12.50 Cr to 10.73 Cr in the same period. The company's total assets grew significantly from 12.29 Cr in Mar'23 to 71.26 Cr in Mar'25, indicating a strong increase in shareholder's funds, which rose to 69.22 Cr by Mar'25. Ca..."
      },
      {
        "title": "When is the next results date for Amwill Health?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-amwill-health-3663078",
        "imagepath": "",
        "date": "2025-10-31 23:17:23",
        "description": "Amwill Health is scheduled to declare its results on November 4, 2025...."
      },
      {
        "title": "How has been the historical performance of Amwill Health?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-amwill-health-3659900",
        "imagepath": "",
        "date": "2025-10-30 22:46:03",
        "description": "Answer:\nThe historical performance of Amwill Health shows a varied trend in financial metrics over the past four years.\n\nBreakdown:\nAmwill Health's net sales increased from 27.61 Cr in Mar'22 to 43.95 Cr in Mar'24, but then decreased to 40.58 Cr in Mar'25. Total operating income followed a similar pattern, rising from 27.61 Cr in Mar'22 to 43.95 Cr in Mar'24 before dropping to 40.58 Cr in Mar'25. The total expenditure also increased from 23.95 Cr in Mar'22 to 28.93 Cr in Mar'25. Operating profit (PBDIT) saw significant growth from 3.66 Cr in Mar'22 to 17.01 Cr in Mar'24, but then fell to 12.36 Cr in Mar'25. Profit before tax mirrored this trend, increasing from 3.33 Cr in Mar'22 to 16.76 Cr in Mar'24, then declining to 11.90 Cr in Mar'25. Profit after tax also rose from 2.57 Cr in Mar'22 to 12.50 Cr in Mar'24, before decreasing to 10.73 Cr in Mar'25. The company's total assets grew significantly from 12.29 ..."
      },
      {
        "title": "Is Amwill Health overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amwill-health-overvalued-or-undervalued-3646808",
        "imagepath": "",
        "date": "2025-10-27 08:07:27",
        "description": "As of 24 October 2025, Amwill Health's valuation grade has moved from very attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 9.69, an EV to EBITDA of 8.66, and a ROCE of 16.92%. \n\nIn comparison to its peers, Amwill Health's PE ratio is significantly lower than that of Sun Pharma, which stands at 35.55, indicating that Amwill may be undervalued relative to this competitor. Additionally, Dr. Reddy's Labs, which is rated very attractive, has a PE ratio of 18.88, further highlighting Amwill's relative valuation position. While the stock has shown a positive return of 0.97% over the past week compared to the Sensex's 0.31%, it has underperformed over the last month with a decline of 11.79% against the Sensex's 3.05% gain, suggesting a potential reevaluation of its market position may be warranted...."
      },
      {
        "title": "Is Amwill Health overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amwill-health-overvalued-or-undervalued-3645845",
        "imagepath": "",
        "date": "2025-10-26 08:07:08",
        "description": "As of 24 October 2025, Amwill Health's valuation grade has moved from very attractive to fair. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 9.69, an EV to EBITDA of 8.66, and a ROE of 15.50%. \n\nIn comparison to its peers, Amwill Health's PE ratio is significantly lower than that of Sun Pharma, which stands at 35.55, indicating that Amwill Health may be undervalued relative to this competitor. Additionally, Dr. Reddy's Labs, which is rated very attractive, has a PE of 18.88, further emphasizing Amwill's relative valuation position. Notably, while Amwill Health has shown a 1-week stock return of 0.97%, it has underperformed the Sensex over the past month, which returned 3.05%...."
      },
      {
        "title": "Is Amwill Health overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amwill-health-overvalued-or-undervalued-3645398",
        "imagepath": "",
        "date": "2025-10-25 08:05:38",
        "description": "As of 24 October 2025, Amwill Health's valuation grade has moved from very attractive to fair, indicating a shift in market perception. The company is currently fairly valued based on its financial metrics, with a PE ratio of 9.69, an EV to EBIT of 9.02, and an ROCE of 16.92%. Compared to its peers, Amwill Health's valuation stands out; for instance, Sun Pharma is considered expensive with a PE ratio of 35.55, while Dr. Reddy's Labs is very attractive with a PE of 18.88.\n\nIn the context of the broader market, Amwill Health's stock has shown a return of 0.97% over the past week, outperforming the Sensex, which returned 0.31%. However, the company's performance over the last month has lagged, with a decline of 11.79% compared to a 3.05% increase in the Sensex. Overall, Amwill Health appears to be fairly valued in the current market landscape...."
      },
      {
        "title": "Why is Amwill Health falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-amwill-health-fallingrising-3630332",
        "imagepath": "",
        "date": "2025-10-18 00:14:31",
        "description": "As of 17-Oct, Amwill Health Care Ltd is experiencing a decline in its stock price, currently at Rs 51.50, which represents a decrease of Rs 2.4 or 4.45%. The stock has underperformed significantly today, opening with a loss of 3.88% and touching an intraday low of Rs 51.5. It is also trading below all key moving averages, indicating a bearish trend. Over the past week, the stock has dropped by 5.50%, and in the last month, it has decreased by 18.11%. Although there has been a notable increase in investor participation, with delivery volume rising by 78.57% against the 5-day average, the overall performance remains weak, and the stock is close to its 52-week low.\n\nIn the broader market context, the Sensex has shown a positive return of 1.76% over the past week and 1.52% over the past month, contrasting sharply with Amwill Health's negative performance. This divergence highlights the stock's struggles relativ..."
      }
    ],
    "total": 174,
    "sid": "10039537",
    "stock_news_url": "https://www.marketsmojo.com/news/amwill-health-care-10039537"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Board Meeting Outcome For The Meeting Of The Board Of Directors Held On November 04 2025",
      "datetime": "04-Nov-2025",
      "details": "Disclosure under Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended (SEBI Listing Regulations) - Outcome of the meeting of the Board of Directors held on November 04 2025 and Approved Statement of Deviation(s) and variation(s) under Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financial Results For The Half Year Ended September 30 2025.",
      "datetime": "04-Nov-2025",
      "details": "Unaudited Financial Results for the half year ended September 30 2025 pursuant to Regulations 33 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "SUBMISSION OF STATEMENT OF DEVIATION OR VARIATION IN UTILIZATION OF FUNDS RAISED THROUGH INITIAL PUBLIC OFFER (IPO)",
      "datetime": "04-Nov-2025",
      "details": "A statement of Deviation or Variuation pusuant to the Regulation 32 of SEBI (LODR) Regulation 2015 be and here by attached.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Amwill Health overvalued or undervalued?

2025-11-09 08:12:12

As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios supporting this assessment include a PE ratio of 9.06, an EV to EBIT of 7.64, and an ROCE of 18.23%. In comparison to its peers, Amwill Health's valuation metrics stand out, particularly against Sun Pharma, which is deemed expensive with a PE ratio of 35.17, and Divi's Lab, classified as very expensive with a PE ratio of 71.11. This stark contrast highlights Amwill Health's attractive valuation within the pharmaceuticals and biotechnology sector. Additionally, while Amwill Health has experienced a decline in stock price recently, it remains undervalued relative to its peers, reinforcing the potential for future upside....

Is Amwill Health overvalued or undervalued?

2025-11-08 08:12:14

As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently deemed undervalued, with a PE ratio of 9.06, an EV to EBIT ratio of 7.64, and an EV to EBITDA ratio of 7.34. These figures suggest that Amwill Health is trading at a discount compared to its peers in the pharmaceuticals and biotechnology sector. In comparison, Sun Pharma is classified as expensive with a PE ratio of 35.17, while Dr. Reddy's Labs is attractive with a PE of 17.43. This stark contrast highlights Amwill Health's favorable position in the market. Additionally, the company's return metrics, such as a ROCE of 18.23% and ROE of 14.68%, further reinforce its strong operational performance despite recent stock declines compared to the Sensex....

How has been the historical performance of Amwill Health?

2025-11-04 23:00:10

Answer: The historical performance of Amwill Health shows a fluctuating trend in key financial metrics over the past four years. Breakdown: Amwill Health's net sales increased from 27.61 Cr in Mar'22 to 43.95 Cr in Mar'24, before declining to 40.58 Cr in Mar'25. Total operating income followed a similar pattern, rising to 43.95 Cr in Mar'24 and then decreasing to 40.58 Cr in Mar'25. The total expenditure also rose from 23.95 Cr in Mar'22 to 28.93 Cr in Mar'25. Operating profit, excluding other income, peaked at 16.67 Cr in Mar'24 but fell to 11.65 Cr in Mar'25. Profit before tax showed a similar decline from 16.76 Cr in Mar'24 to 11.90 Cr in Mar'25, while profit after tax decreased from 12.50 Cr to 10.73 Cr in the same period. The company's total assets grew significantly from 12.29 Cr in Mar'23 to 71.26 Cr in Mar'25, indicating a strong increase in shareholder's funds, which rose to 69.22 Cr by Mar'25. Ca...

When is the next results date for Amwill Health?

2025-10-31 23:17:23

Amwill Health is scheduled to declare its results on November 4, 2025....

How has been the historical performance of Amwill Health?

2025-10-30 22:46:03

Answer: The historical performance of Amwill Health shows a varied trend in financial metrics over the past four years. Breakdown: Amwill Health's net sales increased from 27.61 Cr in Mar'22 to 43.95 Cr in Mar'24, but then decreased to 40.58 Cr in Mar'25. Total operating income followed a similar pattern, rising from 27.61 Cr in Mar'22 to 43.95 Cr in Mar'24 before dropping to 40.58 Cr in Mar'25. The total expenditure also increased from 23.95 Cr in Mar'22 to 28.93 Cr in Mar'25. Operating profit (PBDIT) saw significant growth from 3.66 Cr in Mar'22 to 17.01 Cr in Mar'24, but then fell to 12.36 Cr in Mar'25. Profit before tax mirrored this trend, increasing from 3.33 Cr in Mar'22 to 16.76 Cr in Mar'24, then declining to 11.90 Cr in Mar'25. Profit after tax also rose from 2.57 Cr in Mar'22 to 12.50 Cr in Mar'24, before decreasing to 10.73 Cr in Mar'25. The company's total assets grew significantly from 12.29 ...

Is Amwill Health overvalued or undervalued?

2025-10-27 08:07:27

As of 24 October 2025, Amwill Health's valuation grade has moved from very attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 9.69, an EV to EBITDA of 8.66, and a ROCE of 16.92%. In comparison to its peers, Amwill Health's PE ratio is significantly lower than that of Sun Pharma, which stands at 35.55, indicating that Amwill may be undervalued relative to this competitor. Additionally, Dr. Reddy's Labs, which is rated very attractive, has a PE ratio of 18.88, further highlighting Amwill's relative valuation position. While the stock has shown a positive return of 0.97% over the past week compared to the Sensex's 0.31%, it has underperformed over the last month with a decline of 11.79% against the Sensex's 3.05% gain, suggesting a potential reevaluation of its market position may be warranted....

Is Amwill Health overvalued or undervalued?

2025-10-26 08:07:08

As of 24 October 2025, Amwill Health's valuation grade has moved from very attractive to fair. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 9.69, an EV to EBITDA of 8.66, and a ROE of 15.50%. In comparison to its peers, Amwill Health's PE ratio is significantly lower than that of Sun Pharma, which stands at 35.55, indicating that Amwill Health may be undervalued relative to this competitor. Additionally, Dr. Reddy's Labs, which is rated very attractive, has a PE of 18.88, further emphasizing Amwill's relative valuation position. Notably, while Amwill Health has shown a 1-week stock return of 0.97%, it has underperformed the Sensex over the past month, which returned 3.05%....

Is Amwill Health overvalued or undervalued?

2025-10-25 08:05:38

As of 24 October 2025, Amwill Health's valuation grade has moved from very attractive to fair, indicating a shift in market perception. The company is currently fairly valued based on its financial metrics, with a PE ratio of 9.69, an EV to EBIT of 9.02, and an ROCE of 16.92%. Compared to its peers, Amwill Health's valuation stands out; for instance, Sun Pharma is considered expensive with a PE ratio of 35.55, while Dr. Reddy's Labs is very attractive with a PE of 18.88. In the context of the broader market, Amwill Health's stock has shown a return of 0.97% over the past week, outperforming the Sensex, which returned 0.31%. However, the company's performance over the last month has lagged, with a decline of 11.79% compared to a 3.05% increase in the Sensex. Overall, Amwill Health appears to be fairly valued in the current market landscape....

Why is Amwill Health falling/rising?

2025-10-18 00:14:31

As of 17-Oct, Amwill Health Care Ltd is experiencing a decline in its stock price, currently at Rs 51.50, which represents a decrease of Rs 2.4 or 4.45%. The stock has underperformed significantly today, opening with a loss of 3.88% and touching an intraday low of Rs 51.5. It is also trading below all key moving averages, indicating a bearish trend. Over the past week, the stock has dropped by 5.50%, and in the last month, it has decreased by 18.11%. Although there has been a notable increase in investor participation, with delivery volume rising by 78.57% against the 5-day average, the overall performance remains weak, and the stock is close to its 52-week low. In the broader market context, the Sensex has shown a positive return of 1.76% over the past week and 1.52% over the past month, contrasting sharply with Amwill Health's negative performance. This divergence highlights the stock's struggles relativ...

View All News